On 25 August 2010, orphan designation (EU/3/10/767) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[188.8.131.52(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene for the treatment of post-essential thrombocythaemia myelofibrosis.
The sponsorship was transferred to Baxter Innovations GmbH, Austria, in March 2015.
The sponsorship was transferred to CTI Life Sciences Ltd, United Kingdom, in November 2016 and subsequently to CTI Life Sciences Deutschland GmbH, Germany, in May 2019.
This medicine is now known as pacritinib.
EU/3/10/767: Public summary of opinion on orphan designation: 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[184.108.40.206(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene for the treat... (PDF/137.48 KB)
First published: 18/10/2010
Last updated: 13/05/2015
|Disease / condition||
Treatment of post-essential thrombocythaemia myelofibrosis
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.